For immediate release
Global Green, Inc. Strengthens
Board of Directors and Management Team and Receives
Advance in Funds from Chairman and CEO to Support Company's Growth
--------------------------------------------------------------------------------
Latest initiatives to support corporate growth strategy
Tallahassee, Fla - January 16, 2013 - Global Green, Inc. (OTCBB:GOGC) today
announced that Konky Sotomayor, DVM, the developer of Salmogenics, has been
appointed to the Board of Directors and to the position within the Company of
Chief Scientist and Vice President - R&D.
Global Green also announced that Dr. Mehran Ghazvini, Chairman and CEO, has
advanced the Company $300,000 to support the Company's growth. This amount will
be paid back to Dr. Ghazvini at a future date in preferred shares, cash or a
combination of both.
Dr. Sotomayor graduated with honors as a Doctor in Veterinary Medicine and
Zootechny in the Veterinary Medicine Faculty from the State University of
Guayaquil in Ecuador. He attended the prestigious Lantanisbruk Universitet in
Uppsala, Sweden, renowned for their International Science Program. The program
assists countries in strengthening their domestic research capacity within the
chemical, physical and the mathematical sciences. Dr. Sotomayor has worked in
private laboratory-managing research and development positions since 1979
including being a principal of Nutritional Health Institute Laboratories, LLC
("NHIL"). NHIL is Global Green's research affiliate and majority shareholder. He
has extensive experience in isolation of infectious disease agents and
manufacturing of the corresponding vaccines.
Dr. Ghazvini stated, "Dr. Sotomayor, the developer of the Salmogenics, the
Company`s patented Salmonella vaccine, is a perfect addition to our Board of
Directors. His character, strong background and an extensive track record in
animal infectious disease research and laboratory diagnostics makes him an
important asset. As we execute our core strategy and work to build a pipeline of
high value drug discovery and development programs to deliver tangible results,
Dr. Sotomayor's leadership as Chief Scientist and VP - R&D will be critical."
The Salmogenics vaccine is in its last stages of testing and trials before the
final United States Department of Agriculture/Food Safety and Inspection Service
("USDA") approval for its commercial application.
Global Green, Inc. is a green pharmaceutical company committed to identifying
technology platforms and commercializing products that contain natural organisms
that are not genetically modified, utilizing pharmaceutical standards.
Salmogenics, the Company's flagship product, was developed by Nutritional Health
Institute Laboratories, LLC, research affiliate and majority shareholder. The
vaccine is currently in the final stage of the USDA approval process. For more
information, visit www.globalgreeninc.org.
Forward-Looking Statement
This press release may contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned
that such forward-looking statements involve risks and uncertainties, which
include among others, the inherent uncertainties associated with smaller
reporting companies, including without limitation, other risks detailed from
time to time in the Company's periodic reports filed with the Securities and
Exchange Commission.
Contact:
Pam Lagano
plagano@globalgreeninc.org
727.480.3082